What release profile would you like to see in an extended-release midodrine?
Founded by fathers of POTS patients, Dyscovri Therapeutics is a stealth-mode company developing an oral, extended-release midodrine.
To help inform the development of our formulation, we're surveying stakeholders to understand the extended-release profile that would be most useful to treat POTS.
Thank you so much for your help!